

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

NCT06967480

Status RECRUITING
Sponsor Alexion Pharmaceuticals, Inc.
Enrollment 40 participants

Key Eligibility Criteria

Inclusion (10)

- Diagnosis of MG confirmed by:
 - History of a positive serologic test for anti-AChR antibodies, and
 - One of the following:
 - History of abnormal neuromuscular transmission test demonstrated by single fibre electromyography or repetitive nerve stimulation
 - History of positive anticholinesterase test (e.g., edrophonium chloride test); or
- ... and 5 more (see full listing online)

Exclusion (11)

- Patient unable to understand and sign the informed consent
 - Hypersensitivity to the active substance or to any of the excipients of the study product
 - Patient for whom the study product is contraindicated according to SmPC
 - Previous treatment with C5 inhibitors
 - Last rituximab infusion performed < 6 months before T-4 (Enrolment)
- ... and 6 more (see full listing online)

Locations (23 total)

Clinical Trial Site, Bergamo, Italy
Clinical Trial Site, Bologna, Italy
Clinical Trial Site, Bologna, Italy
... and 20 more locations

<https://clinicaltrials.gov/study/NCT06967480>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.